Cover Image
市場調查報告書

內分泌學藥物的全球市場:2016∼2020年

Global Endocrinology Drugs Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 356778
出版日期 內容資訊 英文 118 Pages
訂單完成後即時交付
價格
Back to Top
內分泌學藥物的全球市場:2016∼2020年 Global Endocrinology Drugs Market 2016-2020
出版日期: 2016年04月19日 內容資訊: 英文 118 Pages
簡介

內分泌疾病,廣泛分為引起荷爾蒙缺乏的內分泌腺分泌不足,引起過剩荷爾蒙分泌的分泌過多,及內分泌腺的腫瘤3個類別。全球內分泌學藥物市場,預計2016∼2020年,以年複合成長率6.69%擴大。

本報告提供全球內分泌學藥物市場現狀與至2020年的成長預測,市場趨勢與課題,各地區趨勢,主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 主要購買標準

第6章 產品研發線

第7章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 各用途的市場

第9章 全球糖尿病藥物市場

第10章 全球睪固酮置換療法市場

第11章 全球人體生長荷爾蒙市場

第12章 全球甲狀腺荷爾蒙疾病治療藥市場

第13章 各地區市場市場區隔

  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第14章 推動市場的要素

  • 內分泌荷爾蒙相關疾病的罹患率上升
  • 有潛力的藥劑開發平台
  • 藥物輸送技術的演進
  • 生技仿製藥藥物的嚴格法律規章

第15章 促進要素的影響

第16章 市場課題

  • 非專利的崛起
  • 副作用與相關風險
  • 科學性社會的疑慮
  • 低的診斷率

第17章 促進要素與課題的影響

第18章 市場趨勢

第19章 供應商環境

  • 競爭模式
  • 市場佔有率分析:2015年
  • Novo Nordisk
  • Sanofi
  • Merck
  • Eli Lilly
  • AstraZeneca
  • AbbVie
  • 其他值得注意的供應商

第20章 附錄

第21章 關於Technavio

圖表

目錄
Product Code: IRTNTR9023

About Endocrinology Drugs

Endocrinology deals with the study of the endocrine system, including the biochemical and physiological functions of the hormones, cells, and tissues of the endocrine glands. Endocrine disorders can be broadly subdivided into three categories: endocrine gland hyposecretion, which causes hormone deficiency, endocrine gland hypersecretion, which causes excess hormone secretion, and tumors in the endocrine gland. The endocrine disorders considered for the present report include diabetes, human growth hormone deficiency, thyroid disorders, and male hypogonadism.

Technavio's analysts forecast the global endocrinology drugs market to grow at a CAGR of 6.69% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global endocrinology drugs market for 2015-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs, generics, and biosimilars used to treat and prevent type 1 and type 2 diabetes, human growth hormone deficiency, hypogonadism, and thyroid gland disorders.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Endocrinology Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AbbVie Inc.
  • AstraZeneca PLC
  • Eli Lilly and Co.
  • Merck & Co
  • Novo Nordisk AS
  • Sanofi SA

Other Prominent Vendors

  • Acerus Pharmaceuticals
  • Acrux DDS
  • Adocia
  • Æterna Zentaris
  • Akros Pharma
  • Allergan
  • Amgen
  • Antares Pharma
  • Ascendis Pharma
  • Astellas Pharma
  • Baxalta
  • Bayer HealthCare Pharmaceuticals
  • BHV Pharma
  • Biocon
  • Biodel
  • Boehringer Ingelheim
  • ChipScreen Biosciences
  • Clarus Therapeutics
  • ConjuChem
  • Critical Pharmaceuticals
  • CureDm
  • CymaBay Therapeutics
  • Daiichi Sankyo
  • Dance Biopharm
  • DiaMedica
  • Diamyd Therapeutics
  • Diasome Pharmaceuticals
  • DiaVacs
  • Dong-A ST
  • Eisai
  • Elcelyx Therapeutics
  • Endo Pharmaceuticals
  • Exsulin
  • Ferring Pharmaceuticals
  • Gan & Lee Pharmaceuticals
  • Genentech
  • Generex
  • Genexine
  • Genfit
  • GSK
  • HanAll BioPharma
  • Hanmi Pharmaceutical
  • Hua Medicine
  • ILTOO Pharma
  • Intarcia Therapeutics
  • InteKrin Therapeutics
  • Intrexon
  • Ionis Pharmaceuticals
  • Ipe
  • Islet Sciences
  • Janssen Pharmaceuticals
  • Japan Tobacco
  • Juniper Pharmaceuticals
  • Kadmon Corporation
  • Kamada
  • KinDex Pharmaceuticals
  • Kissei Pharmaceutical
  • Kotobuki
  • Lexicon Pharmaceuticals
  • LG Life Sciences
  • Ligand Pharmaceuticals
  • Lipocine
  • Living Cell Technologies
  • MacroGenics
  • MannKind
  • MedImmune
  • Melior Pharmaceuticals
  • Metabolic Solutions Development Company
  • MetP Pharma
  • Mitsubishi Tanabe Pharma
  • Mylan
  • NGM Biopharmaceuticals
  • Novartis
  • NuSirt Biopharma
  • OPKO Biologics
  • Oramed Pharmaceuticals
  • Osiris Therapeutics
  • Peptron
  • Perle Biosciences
  • Pfizer
  • PhaseBio Pharmaceuticals
  • Poxel
  • ProStrakan Group
  • REGiMMUNE
  • Repros Therapeutics
  • Roche
  • Sanwa Kagaku Kenkyusho
  • Sirona Biochem
  • Strongbridge Biopharma
  • Takeda Pharmaceuticals
  • TesoRx Pharma
  • Teva Pharmaceutical
  • Theracos
  • Theratechnologies
  • Toleranzia
  • Tolerion
  • Transition Therapeutics
  • VeroScience
  • Versartis
  • vTv Therapeutics
  • XBiotech
  • Xeris Pharmaceuticals
  • XOMA

Market driver

  • Increase in prevalence of endocrine hormone-related diseases
  • For a full, detailed list, view our report

Market challenge

  • Generic erosion
  • For a full, detailed list, view our report

Market trend

  • Increase in outsourcing
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Key buying criteria

PART 06: Pipeline portfolio

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by application

PART 09: Global diabetes drugs market

  • Introduction
  • Market overview
  • Market drivers
  • Market challenges
  • Market trends
  • Vendor analysis of global diabetes drugs market

PART 10: Global testosterone replacement therapy market

  • Introduction
  • Market overview
  • Market drivers
  • Market challenges
  • Market trends
  • Vendor analysis of global testosterone replacement therapy market

PART 11: Global human growth hormone market

  • Introduction
  • Market overview
  • Market drivers
  • Market challenges
  • Market trends
  • Vendor analysis of global human growth hormone market

PART 12: Global thyroid hormone disorder drugs market

  • Market overview
  • Market drivers
  • Market challenges
  • Market trends
  • Vendor analysis of global thyroid disorder drugs market

PART 13: Geographical segmentation

  • Global endocrinology drugs market by geographical segmentation 2015-2020
  • Endocrinology drugs market in Americas
  • Endocrinology drugs market in EMEA
  • Endocrinology drugs market in APAC

PART 14: Market drivers

  • Increase in prevalence of endocrine hormone-related diseases
  • Promising drug pipeline
  • Advances in drug delivery technology
  • Stringent regulatory conditions for biosimilar drugs

PART 15: Impact of drivers

PART 16: Market challenges

  • Generic erosion
  • Side effects and associated risks
  • Rising concerns in scientific community
  • Low diagnosis rate

PART 17: Impact of drivers and challenges

PART 18: Market trends

  • Development of drugs with novel mechanism and technologies
  • Strategic alliances and M&A
  • Increased awareness
  • Increase in outsourcing

PART 19: Vendor landscape

  • Competitive scenario
  • Market share analysis 2015
  • Novo Nordisk
  • Sanofi
  • Merck
  • Eli Lilly
  • AstraZeneca
  • AbbVie
  • Other prominent vendors

PART 20: Appendix

  • List of abbreviations

PART 21: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Key buying criteria for endocrinology drugs
  • Exhibit 03: Pipeline portfolio: Global diabetes drugs market
  • Exhibit 04: Pipeline portfolio: Global thyroid disorder drugs market
  • Exhibit 05: Pipeline portfolio: Global human growth hormone drugs market
  • Exhibit 06: Pipeline portfolio: Global testosterone drugs market
  • Exhibit 07: Global endocrinology drugs market 2015-2020 ($ billions)
  • Exhibit 08: Five forces analysis
  • Exhibit 09: Market segmentation of global endocrinology drugs market by application
  • Exhibit 10: Global endocrinology drugs market: YoY growth and revenue based on application 2015-2020
  • Exhibit 11: Global diabetes market by type of disease 2015
  • Exhibit 12: Top-selling diabetes drugs based on sales 2015 ($ billions)
  • Exhibit 13: Market share of global diabetes drugs in global pharmaceutical market 2015
  • Exhibit 14: Global diabetes drugs market 2015-2020 ($ billions)
  • Exhibit 15: Market share analysis of vendors in global diabetes drugs market
  • Exhibit 16: Global testosterone replacement therapy market 2015-2020 ($ billions)
  • Exhibit 17: Global human growth hormone market 2015-2020 ($ billions)
  • Exhibit 18: Global human growth hormone market 2015-2020 ($ billions)
  • Exhibit 19: Segmentation of global endocrinology drugs market based on geography 2015
  • Exhibit 20: Global endocrinology drugs market revenue by geography 2015-2020 ($ billions)
  • Exhibit 21: Global endocrinology drugs market by geography 2015-2020
  • Exhibit 22: Endocrinology drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 23: Endocrinology drugs market in EMEA 2015-2020 ($ billions)
  • Exhibit 24: Endocrinology drugs market in APAC 2015-2020 ($ billions)
  • Exhibit 25: Global endocrinology drugs market: YoY growth and revenue based on geography 2015-2020
  • Exhibit 26: Impact of drivers
  • Exhibit 27: Impact of drivers and challenges
  • Exhibit 28: Revenues from the sales of top seven products in type 2 diabetes market 2012-2014 ($ billions)
  • Exhibit 29: Novo Nordisk: YoY revenue and growth rate of human insulins 2013-2015 ($ billions)
  • Exhibit 30:
  • Exhibit 31: Novo Nordisk: Geographical segmentation of human insulins 2015
  • Exhibit 32: Novo Nordisk: YoY revenue and sales growth of Levemir 2013-2015 ($ billions)
  • Exhibit 33: Geographical segmentation of Levemir 2015
  • Exhibit 34: Novo Nordisk: YoY growth and revenue of NovoLog/NovoRapid 2013-2015 ($ billions)
  • Exhibit 35: Novo Nordisk: Revenue of NovoLog/NovoRapid by geography 2015
  • Exhibit 36: Novo Nordisk: YoY growth and revenue of NovoMix/NovoLog mix 2013-2015 ($ billions)
  • Exhibit 37: Novo Nordisk: Geographical split of revenues of NovoMix 2015
  • Exhibit 38: Novo Nordisk: Revenue generated from net product sales of new-generation insulins 2013-2015 ($ millions)
  • Exhibit 39: Novo Nordisk: YoY revenue and growth rate of Victoza 2013-2015 ($ billions)
  • Exhibit 40: Geographical segmentation of Victoza 2015
  • Exhibit 41: Novo Nordisk: YoY growth and revenue of Novonorm, Prandin, and PrandiMet 2012-2014 ($ millions)
  • Exhibit 42: Novo Nordisk: YoY growth rate and revenue of Norditropin 2013-2015 ($ billions)
  • Exhibit 43: Novo Nordisk: Revenue of Norditropin by geography 2015
  • Exhibit 44: Novo Nordisk: Key takeaways
  • Exhibit 45: Sanofi: YoY revenue and growth rate of Lantus 2013-2015 ($ billions)
  • Exhibit 46: Sanofi: Geographical segmentation of Lantus by revenue 2015
  • Exhibit 47: Sanofi: YoY revenue and growth rate of Amaryl 2013-2015 ($ millions)
  • Exhibit 48: Sanofi: Amaryl geographical segmentation by revenue 2015
  • Exhibit 49: Sanofi: YoY revenue and growth rate of Apidra 2013-2015 ($ million)
  • Exhibit 50: Sanofi: Geographical segmentation of Toujeo by revenue 2015 (%)
  • Exhibit 51: Sanofi: YoY revenue and growth rate of Insuman 2013-2015 ($ millions)
  • Exhibit 52: Sanofi: YoY revenue and growth rate of Lyxumia 2013-2015 ($ millions)
  • Exhibit 53: Sanofi: Key takeaways
  • Exhibit 54: Merck: YoY revenue and growth rate of Januvia 2013-2015 ($ billions)
  • Exhibit 55: Merck: YoY revenue and growth rate of Januvia 2013-2015 ($ billions)
  • Exhibit 56: Merck: Key takeaways
  • Exhibit 57: Eli Lilly: YoY revenue and growth rate of Humalog 2013-2015 ($ billions)
  • Exhibit 58: Eli Lilly: YoY revenue and growth rate of Humulin 2013-2015 ($ billions)
  • Exhibit 59: Eli Lilly: YoY revenue and growth rate of Trajenta and Jentadueto 2012-2015 ($ billions)
  • Exhibit 60: Eli Lilly: YoY revenue of Trulicity 2014-2015 ($ millions)
  • Exhibit 61: Eli Lilly: Trulicity geographical segmentation by revenue 2015
  • Exhibit 62: Eli Lilly: Key takeaways
  • Exhibit 63: AstraZeneca: YoY revenue and growth rate of Farxiga 2013-2015 ($ millions)
  • Exhibit 64: AstraZeneca: Geographical segmentation of Farxiga/Forxiga by revenue 2015
  • Exhibit 65: AstraZeneca: YoY revenue and growth rate of Byetta 2013-2015 ($ million)
  • Exhibit 66: AstraZeneca: YoY revenue and growth rate of Bydureon 2013-2015 ($ millions)
  • Exhibit 67: AstraZeneca: YoY revenue and growth rate of Kombiglyze/Komboglyze/Onglyza 2013-2015 ($ millions)
  • Exhibit 68: AstraZeneca: Key takeaways
  • Exhibit 69: AbbVie: YoY revenue and growth rate of AndroGel 2013-2015 ($ millions)
  • Exhibit 70: AbbVie: YoY revenue and growth rate of Synthroid 2013-2015 ($ millions)
  • Exhibit 71: AbbVie: Key takeaways
Back to Top